TREATMENT OF POLYCYTHEMIA VERA WITH TRIETHYLENE MELAMINE

1 September 1952

journal article
research article
Published by American Medical Association (AMA) in A.M.A. Archives of Internal Medicine

Vol. 90 (3) , 379-388
https://doi.org/10.1001/archinte.1952.00240090100008

Abstract

THE PURPOSE of this paper is to present data on the treatment of polycythemia vera with triethylene melamine (T. E. M.), based on the study of 30 cases followed for an average period of more than one year. Triethylene melamine, a compound which has nitrogen-mustard-like action, has the advantage that it is effective upon oral administration. The development of triethylene melamine, its pharmacological properties, and its use in patients with lymphomas, leukemia, and various carcinomas have been extensively discussed in papers by Karnofsky and associates¹and Wright and co-workers.²Because of its ease of administration and its depressant effects upon hematopoiesis, which appear to resemble those of nitrogen mustard (methyl-bisortris[β-choroethyl] amine hydrochloride) and x-irradiation,³it appeared that triethylene melamine might be of value in the treatment of polycythemia vera. Emphasis upon the treatment of polycythemia by bone marrow inhibition is largely derived from the work of Lawrence,⁴

Keywords

This publication has 0 references indexed in Scilit: